4.7 Review

Resveratrol supplementation: Where are we now and where should we go?

期刊

AGEING RESEARCH REVIEWS
卷 21, 期 -, 页码 1-15

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.arr.2015.01.002

关键词

Resveratrol; Bioavailability; Metabolism; Clinical trials; Translational research

资金

  1. Intramural Research Program of the National Institute on Aging, National Institutes of Health

向作者/读者索取更多资源

Pre-clinical findings have provided mounting evidence that resveratrol, a dietary polyphenol, may confer health benefits and protect against a variety of medical conditions and age-related complications. However, there is no consistent evidence of an increased protection against metabolic disorders and other ailments when comparing studies in laboratory animals and humans. A number of extraneous and potential confounding variables can affect the outcome of clinical research. To date, most of the studies that have investigated the effect of resveratrol administration on patient outcomes have been limited by their sample sizes. In this review, we will survey the latest advances regarding the timing, dosage, formulation, bioavailability, toxicity of resveratrol, and resveratrol-drug interactions in human studies. Moreover, the present report focuses on the actions of resveratrol treatment in combating diseases, such as cancer, diabetes, neurodegeneration, cardiovascular disease, and other age-related ailments. Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据